Option exercise expands executive's long-term equity stake to 612,251 shares, now valued at $18.37 million based on August 7 market close.

Murdoch exercised options at $18 per share, increasing his total beneficial ownership to ~8 million shares valued at $161 million, representing a 13% stake.

SHANGHAI and SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- Hengrui Pharma (Hengrui), and Braveheart Bio today announced results from a multi-center, randomized, open-label Phase 2 dose-ranging study ...

July 30 (Reuters) - Braveheart Bio is targeting a valuation of up to $1.2 billion in its U.S. initial public offering, the clinical-stage biopharmaceutical company said on Thursday. The San Francisco, ...

Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, ...

A new trailer for Braveheart 2 starring Mel Gibson has just been released, creating a buzz online. The trailer shows a plot that delves into a new chapter of the story set up in the original film. Now ...

Braveheart Bio Inc., a clinical-stage biopharmaceutical company backed by a16z, is seeking to raise as much as $318.8 million in an initial public offering, adding to a growing pipeline of listings in ...